

Synthesis of optically active α -trifluoromethylamines by rearrangement of β -amino- α -trifluoromethyl alcohols

Z. Neouchy,^a D. Gomez Pardo^{*a} and J. Cossy^{*a}

^a *Laboratoire de Chimie Organique, Institute of Chemistry, Biology and Innovation (CBI),
ESPCI Paris/CNRS/PSL Research University, 10 rue Vauquelin, Paris 75231 Cedex 05, France*

* E-mail: domingo.gomez-pardo@espci.fr

* E-mail: janine.cossy@espci.fr

Supporting Information

Table of contents:

General information.....	S-2
1. Preparation of the starting material.....	S-3
a. Swern oxidation.....	S-3
b. Trifluoromethylation reaction.....	S-5
2. Treatment with DAST.....	S-12
3. Rearrangement of β -amino- α -trifluoromethyl alcohols	S-15
a. Synthesis of β -trifluoromethyl- β -aminoalcohol.....	S-16
b. Synthesis of α -trifluoromethylamines.....	S-22
4. Application of α -trifluoromethylamines	S-32
5. Copies of the ^1H , ^{13}C NMR and ^{19}F spectra.....	S-34

General information

All reactions were carried out under an argon atmosphere unless otherwise specified. Flasks were oven-dried at 120 °C and cooled under argon prior to use. CH₂Cl₂ was distilled over calcium hydride, THF and Et₂O were distilled over sodium/benzophenone prior to use. All other commercially available chemicals were used directly without purification.

¹H NMR spectra were recorded on a Bruker Avance 400 at 400 MHz. The chemical shifts δ are reported in ppm relative to tetramethylsilane (TMS) or residual protonated solvents (TMS: δ_{H} = 0.00 ppm, CHCl₃: δ_{H} = 7.26 ppm). The multiplicity is designated by the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, pent = quintet, hex = hexuplet, hept = heptuplet, m = multiplet, br = broad, app = apparent. Coupling constants *J* are reported in Hertz (Hz).

¹⁹F spectra were recorded on a Bruker Avance 400 at 376 MHz. The chemical shifts δ are reported in ppm. Coupling constants *J* are reported in Hertz (Hz).

¹³C NMR spectra were recorded on a Bruker Avance 400 at 100 MHz. The chemical shifts δ are reported in ppm relative to the solvent as an internal indicator (CDCl₃ δ 77.16 ppm). Coupling constants *J* are reported in Hertz (Hz).

TLCs were performed on Merck 60F₂₅₄ silica gel plates and visualized with UV lamp (254 nm), and by treatment with a solution of KMnO₄/K₂CO₃/AcOH/H₂O or with a solution of phosphomolybdic acid in ethanol followed by heating.

Flash column chromatography was performed with Merck Geduran Si 60 silica gel (40-63 μ m).

Infrared (IR) spectra were recorded on a Bruker TENSOR™ 27 (IRTF). The samples were prepared as neat films or as fine powders and the wave numbers are reported in cm⁻¹.

Mass spectra with electronic impact (MS-EI) were recorded from a Shimadzu GCMS-QP 2010S (70 eV). High resolution mass spectra (HRMS) were performed by the Centre Regional de Microanalyse (Sorbonne University, Campus Pierre et Marie Curie, Paris, France).

Melting points were determined on a Büchi Melting Point M-560 apparatus with open capillaries.

Optical rotations were measured with an Anton Paar Polarimeter MCP 100 in a 10 cm cell. The concentrations indicated are in g/100mL.

The enantiomeric ratios were determined by supercritical fluid chromatography (SFC) on a chiral stationary phase using a Minigram Berger SFC-Mettler Toledo apparatus, MeOH was used as polar eluent.


1. Preparation of the starting materials

a. Swern oxidation

General procedure¹

To a stirred solution of oxalyl chloride (1.24 equiv) in CH₂Cl₂ (*c* = 0.49 M) at – 78 °C was added DMSO (2.58 equiv). After 15 min, a solution of the commercially available *N,N*-dibenzyl aminoalcohols **1** (1.0 equiv) in CH₂Cl₂ (*c* = 0.4 M) was added. After 30 min, Et₃N (2.63 equiv) was added and the resulting mixture was then partitioned between CH₂Cl₂ and saturated aqueous solution of NaHCO₃. The organic phase was separated and was dried over Na₂SO₄ and then concentrated under reduced pressure to yield aldehydes **2** that were used without further purification in the next step to avoid epimerization. The spectral data of aldehydes **2** are in agreement with those reported in the literature.

(*S*)-2-(Dibenzylamino)-3-phenylpropanal (**2a**)¹



Formula: C₂₃H₂₃NO **MW=** 329.44 g.mol⁻¹

Compound **2a** was synthesized from commercially available *N,N*-dibenzyl-L-phenylalaninol (1.3 g, 4.0 mmol) as a colorless oil (1.2 g, 3.75 mmol, 94%).

IR (neat): ν_{max} 3062, 3028, 2923, 2849, 2806, 1722, 1673, 1637, 1600, 1495, 1453, 1367, 1269, 1177, 1119, 1074, 1028, 979 cm⁻¹.


¹H NMR (CDCl₃, 400 MHz): δ 9.72 (s, 1H), 7.32–7.18 (m, 13H), 7.16–7.14 (m, 2H), 3.82 (d, *J*_{AB} = 13.7 Hz, 2H), 3.67 (d, *J*_{AB} = 13.7 Hz, 2H), 3.56 (dd, *J* = 7.1, 6.4 Hz, 1H), 3.14 (dd, *J*_{AB} = 13.9, 7.3 Hz, 1H), 2.94 (dd, *J*_{AB} = 13.9, 6.1 Hz, 1H).

¹³C NMR (CDCl₃, 100 MHz): δ 202.4, 139.3, 139.0 (2C), 129.6 (2C), 128.9 (4C), 128.6 (2C), 128.5 (4C), 127.5 (2C), 126.4, 68.6, 54.9 (2C), 30.2.

MS (EI, 70 eV): *m/z* (relative intensity) = 329 (M⁺, 0.1), 301 (11), 300 (45), 210 (10), 91 (100), 65 (11).

¹ Andrés, J. M.; Barrio, R.; Martínez, M. A.; Pedrosa, R.; Pérez-Encabo, A. *J. Org. Chem.* **1996**, *61*, 4210–4213.

(S)-2-(Dibenzylamino)propanal (**2b**)¹



Formula: C₁₇H₁₉NO **MW=** 253.35 g.mol⁻¹

Compound **2b** was synthesized from commercially available (S)-(+)-2-(dibenzylamino)-1-propanol (900 mg, 3.49 mmol) as a colorless oil (835.8 mg, 3.30 mmol, 95%).


IR (neat): $\nu_{\max}$ 3062, 3028, 2977, 2807, 1726, 1602, 1494, 1453, 1378, 1325, 1247, 1153, 1075, 1028, 975, 909 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 9.73 (s, 1H), 7.41 (d, J = 7.2 Hz, 4H), 7.34–7.30 (m, 4H), 7.27–7.23 (m, 2H), 3.73 (d, J_{AB} = 13.7 Hz, 2H), 3.57 (d, J_{AB} = 13.7 Hz, 2H), 3.33 (q, J = 6.8 Hz, 1H), 1.18 (d, J = 6.8 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 204.6, 139.1 (2C), 128.9 (4C), 128.6 (4C), 127.5 (2C), 63.0, 55.1 (2C), 6.9.

MS (EI, 70 eV): m/z (relative intensity) = 253 (M⁺, 0.03), 225 ([M⁺+1-[•]CHO]), 224 ([M⁺-[•]CHO], 54), 181 (13), 132 (5), 91 (100), 65 (17).

(S)-2-(Dibenzylamino)-4-methylpentanal (**2c**)¹



Formula: C₂₀H₂₅NO **MW=** 295.43 g.mol⁻¹

Compound **2c** was synthesized from commercially available *N,N*-dibenzyl-L-leucinol (693 mg, 2.33 mmol) as a cloudy colorless oil (578.2 mg, 1.96 mmol, 84%).


IR (neat): $\nu_{\max}$ 3063, 3028, 2955, 2928, 2868, 2805, 1726, 1678, 1603, 1494, 1454, 1366, 1206, 1145, 1075, 1028, 975 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 9.75 (s, 1H), 7.39–7.36 (m, 4H), 7.34–7.30 (m, 4H), 7.27–7.22 (m, 2H), 3.78 (d, J_{AB} = 13.7 Hz, 2H), 3.70 (d, J_{AB} = 13.7 Hz, 2H), 3.22 (t, J = 6.6 Hz, 1H), 1.71 (dt_{app}, J = 13.2, 6.6 Hz, 1H), 1.61 (dt_{app}, J = 13.9, 7.0 Hz, 1H), 1.49 (m, 1H), 0.82 (d, J = 6.6 Hz, 3H), 0.77 (d, J = 6.5 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 204.2, 139.5 (2C), 129.0 (4C), 128.5 (4C), 127.4 (2C), 65.0, 54.9 (2C), 33.2, 25.4, 22.8, 22.6.

MS (EI, 70 eV): m/z (relative intensity) = 295 (M⁺, 0.01), 266 ([M⁺-[•]CHO], 56), 181 (9), 91 (100), 65 (9).

(S)-2-(Dibenzylamino)-3-methylbutanal (**2d**)¹



Formula: C₁₉H₂₃NO **MW=** 281.18 g.mol⁻¹

Compound **2d** was synthesized from commercially available (S)-2-(*N,N*-dibenzylamino)-3-methylbutanol (1.3 g, 4.14 mmol) as a brown oil (1.1 g, 3.96 mmol, 96%).

IR (neat): $\nu_{\max}$ 3062, 3029, 2960, 2929, 2871, 2804, 2722, 1715, 1676, 1602, 1495, 1454, 1367, 1245, 1204, 1142, 1106, 1074, 1028, 975 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 9.82 (d, J = 3.4 Hz, 1H), 7.38–7.30 (m, 8H), 7.26–7.23 (m, 2H), 4.02 (d, J_{AB} = 13.8 Hz, 2H), 3.71 (d, J_{AB} = 13.8 Hz, 2H), 2.72 (dd, J = 10.0, 3.5 Hz, 1H), 2.28 (m, 1H), 1.08 (d, J = 6.7 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 205.3, 139.4 (2C), 128.9 (4C), 128.5 (4C), 127.3 (2C), 71.7, 54.7 (2C), 26.2, 20.3, 20.0.

MS (EI, 70 eV): m/z (relative intensity) = 281 (M⁺, 0.03), 252 ([M⁺–•CHO], 53), 210 (6), 181 (11), 91 (100), 65 (11).

b. Trifluoromethylation reaction

General procedure²

To a stirred solution of the *N,N*-dibenzylaminoaldehydes **2** (1.0 equiv) in THF (c = 0.2 M) at 0 °C was added TMSCF₃ (2.0 equiv). A solution of TBAF (1 M in THF, 2.0 equiv) was added dropwise and the resulting mixture was stirred at rt. After 19 h, the solution was quenched with a saturated aqueous solution of NH₄Cl (20 mL) and stirred for another 30 min. The solution was concentrated under reduced pressure and diluted in CH₂Cl₂. Both layers were separated and the aqueous phase was extracted once with CH₂Cl₂. The organic layer was washed twice with H₂O, dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography (PE/EtOAc) to afford both diastereoisomers of products **3–6**. The *anti/syn* ratio was determined by analysis of ¹⁹F NMR spectra of the crude. The spectral data of compounds **3–6** are in agreement with those reported in the literature. However, for some compounds, the signal of the “CF₃” group is not visible in the ¹³C NMR spectra.

² Ryu, J. H.; Kim, S. A.; Ryu, R. H.; Kim, J. S.; Kim, N. H.; Han, H. Y.; Kim, Y. H.; Youn, W.-N.; Lee, Y.-J.; Son, H. J.; Lee, B.-Y.; Park, S. H.; Lee, J.-Y.; Lee, H. J.; Jung, H. C.; Shin, Y. A.; Lee, J. A.; Lee, B. R.; Sa, J. H. (2011). *PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME*. WO/2011/139107.


(3S)-3-(Dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (**3**)

Compound **3** was synthesized from (*S*)-2-(dibenzylamino)-3-phenylpropanal **2a** (655 mg, 1.99 mmol) as a mixture of two diastereoisomers in a ratio *anti*/*syn* = 79:21 determined from the ¹⁹F NMR spectrum of the crude. Purification by flash column chromatography (PE/EtOAc = 98:2 then 95:5) afforded (+)-*anti*-**3** (416.6 mg, 1.04 mmol, 52%) as a white solid (from hexane/EtOAc) and (+)-*syn*-**3** (155.7 mg, 0.39 mmol, 20%) as a beige solid (from hexane).

For the crude:

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 75.57 (3 x F, CF₃, *syn*), – 75.94 (3 x F, CF₃, *anti*) .

(+)-(2*S*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol [(+)-*anti*-**3**]³



Formula: C₂₄H₂₄F₃NO MW= 399.46 g.mol⁻¹

mp = 106–108 °C.

[α]_D²⁵ + 8.7 (c 0.31, CHCl₃); literature: [α]_D²⁰ – 11.9 (c 1.0, CHCl₃).

IR (neat): $\nu_{\max}$ 3550, 3065, 3030, 2935, 2803, 1605, 1497, 1456, 1349, 1273, 1167, 1142, 1112, 1031, 979, 905 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.27–7.09 (m, 15 H), 4.21 (m, 1H), 3.80 (d, *J*_{AB} = 13.9 Hz, 2H), 3.55 (d, *J*_{AB} = 13.9 Hz, 2H), 3.35 (m, 1H), 3.09 (dd, *J*_{AB} = 14.3, 9.4 Hz, 1H), 2.90 (dd, *J*_{AB} = 14.3, 5.3 Hz, 1H), 2.67 (d, *J* = 5.6 Hz, 1H, OH).

¹³C NMR (CDCl₃, 100 MHz): δ 139.2, 138.9 (2C), 129.6 (2C), 128.9 (4C), 128.5 (6C), 127.3 (2C), 126.4, 125.4 (d_{app}, *J* = 283.3 Hz)*, 68.4 (q, *J* = 29.7 Hz), 59.1, 54.6 (2C), 31.8.

(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 75.64 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 308 ([M⁺⁺–•CH₂Ph], 26), 300 (12), 181 (4), 91 (100), 65 (6).



The enantiomeric excess of (+)-*anti*-**3** (ee > 99%) was determined by super-critical fluid chromatography (SFC) using a chiral stationary phase (OJ-H column, P = 100 bars, flow rate = 4 mL/min, eluent = sc CO₂/MeOH = 90:10, detection at 210 nm).

($\pm$)-*anti*-**3** :⁴


(+)-*anti*-**3** :

³ Andrés, J. M.; Pedrosa, R.; Pérez-Encabo, A. *Eur. J. Org. Chem.* **2004**, 1558–1566.

⁴ Compounds ($\pm$)-*anti*-**3** and ($\pm$)-*syn*-**3** were synthesized from ($\pm$)-**2a** according to the general procedure of the trifluoromethylation (described above).



(+)-(2*R*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol [(+)-*syn*-3]³



Formula: C₂₄H₂₄F₃NO **MW=** 399.46 g.mol⁻¹

mp = 81–83 °C.

[α]_D²⁵ + 28.1 (*c* 0.19, CHCl₃); literature: **[α]_D²⁰** + 30.5 (*c* 1.0, CHCl₃).

IR (neat): ν_{max} 3063, 3029, 2929, 2856, 1603, 1496, 1454, 1366, 1271, 1200, 1162, 1135, 1098, 1029, 964, 904 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.42–7.09 (m, 15 H), 5.16 (br s, 1H, OH), 3.84–3.79 (m, 3H), 3.38–3.36 (m, 3H), 3.12 (dd, *J*_{AB} = 14.6, 9.7 Hz, 1H), 2.97 (dd, *J*_{AB} = 14.6, 3.8 Hz, 1H).

¹³C NMR (CDCl₃, 100 MHz): δ 139.1, 137.7 (2C), 129.5 (2C), 129.3 (4C), 129.0 (2C), 128.7 (4C), 127.7 (2C), 127.0, 69.4 (q, *J* = 29.6 Hz), 58.0, 54.2 (2C), 34.5.

CF₃ is not visible.



¹⁹F NMR (CDCl₃, 376 MHz): δ – 75.69 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 308 ([M⁺ – •CH₂Ph], 30), 300 (12), 181 (4), 91 (100), 65 (7).

The enantiomeric excess of (+)-*syn*-3 (ee > 99%) was determined by super-critical fluid chromatography (SFC) using a chiral stationary phase (OJ-H column, P = 100 bars, flow rate = 4 mL/min, eluent = sc CO₂/MeOH = 95:5, detection at 210 nm).

(±)-*syn*-3 :⁴

(+)-*syn*-3 :




(3S)-3-(Dibenzylamino)-1,1,1-trifluorobutan-2-ol (**4**)

Compound **4** was synthesized from (*S*)-2-(dibenzylamino)propanal **2b** (413 mg, 1.63 mmol) as a mixture of two diastereoisomers in a ratio *anti/syn* = 79:21 determined from the ^{19}F NMR spectrum of the crude. Purification by flash column chromatography (PE/EtOAc = 98:2 and 95:5) afforded (+)-*anti*-**4** (350.6 mg, 1.08 mmol, 67%) as a colorless oil and (+)-*syn*-**4** (92.1 mg, 0.28 mmol, 18%) as a colorless oil.

For the crude:

^{19}F NMR (CDCl_3 , 376 MHz): δ -75.96 (3 x F, CF_3 , *syn*), -76.02 (3 x F, CF_3 , *anti*).

(+)-(2*S*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluorobutan-2-ol [(+)-*anti*-**4**]³



Formula: $\text{C}_{18}\text{H}_{20}\text{F}_3\text{NO}$ **MW=** 323.36 $\text{g}\cdot\text{mol}^{-1}$

$[\alpha]_{\text{D}}^{25} + 24.2$ (*c* 0.19, CHCl_3); literature: $[\alpha]_{\text{D}}^{20} + 27.7$ (*c* 1.0, CHCl_3).

IR (neat): ν_{max} 3416, 3064, 3029, 2991, 2942, 2806, 1602, 1494, 1453, 1367, 1326, 1273, 1152, 1125, 1072, 1028, 905, 845, 745, 697 cm^{-1} .


^1H NMR (CDCl_3 , 400 MHz): δ 7.35–7.29 (m, 8 H), 7.26–7.21 (m, 2 H), 4.10 (m, 1H), 3.74 (d, $J_{\text{AB}} = 13.9$ Hz, 2H), 3.58 (d, $J_{\text{AB}} = 13.9$ Hz, 2H), 3.19 (qd, $J = 7.0, 3.7$ Hz, 1H), 2.71 (br s, 1H, OH), 1.21 (d, $J = 7.0$ Hz, 3H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 139.5 (2C), 128.8 (4C), 128.5 (4C), 127.3 (2C), 125.2 (q, $J = 283.2$ Hz), 71.5 (q, $J = 29.3$ Hz), 54.7 (2C), 52.7, 9.0.

^{19}F NMR (CDCl_3 , 376 MHz) : δ -76.08 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 323 (M^{+} , 0.1), 224 (57), 181 (8), 132 (4), 91 (100), 65 (10).

(+)-(2*R*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluorobutan-2-ol [(+)-*syn*-**4**]³



Formula: C₁₈H₂₀F₃NO **MW=** 323.36 g.mol⁻¹

[α]_D²⁵ + 60.7 (c 0.14, CHCl₃); literature: **[α]_D²⁰** + 74.4 (c 1.0, CHCl₃).

IR (neat): ν_{max} 3256, 3065, 3030, 2976, 2943, 2848, 1603, 1496, 1453, 1365, 1326, 1272, 1154, 1115, 1063, 1029, 905 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.24 (m, 10 H), 5.09 (br s, 1H, OH), 3.79 (d, J_{AB} = 13.9 Hz, 2H), 3.74 (m, 1H), 3.38 (d, J_{AB} = 13.9 Hz, 2H), 3.00 (dq, J = 9.5, 6.7 Hz, 1H), 1.20 (dd, J = 6.7, 1.0 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 137.8 (2C), 129.2 (4C), 128.9 (4C), 127.9 (2C), 125.3 (d_{app}, J = 281.0 Hz)*, 70.4 (q, J = 30.0 Hz), 53.3 (2C), 52.9, 9.5.

(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 76.00 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 323 (M⁺, 0.02), 224 (55), 181 (8), 132 (4), 91 (100), 65 (10).


(3S)-3-(Dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (5)

Compound **5** was synthesized from (S)-2-(dibenzylamino)-4-methylpentanal **2c** (583 mg, 1.93 mmol) as a mixture of two diastereoisomers in a ratio *anti*/*syn* = 72:28 determined from the ¹⁹F NMR spectrum of the crude. Purification by flash column chromatography (PE/EtOAc = 98:2 to 95:5) afforded (–)-*anti*-**5** (362.3 mg, 0.99 mmol, 51%) as a colorless oil and (+)-*syn*-**5** (168.3 mg, 0.46 mmol, 24%) as a colorless oil.

For the crude:

¹⁹F NMR (CDCl₃, 376 MHz): δ – 75.72 (3 x F, CF₃, *syn*), – 76.10 (3 x F, CF₃, *anti*) .

(–)-(2S,3S)-3-(Dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol [(–)-*anti*-**5**]³



Formula: C₂₁H₂₆F₃NO **MW=** 365.44 g.mol⁻¹

[α]_D²⁵ – 11.5 (c 0.48, CHCl₃); literature: **[α]_D²⁰** – 12.3 (c 1.0, CHCl₃).

IR (neat): ν_{max} 3426, 3064, 3030, 2956, 2869, 2801, 1602, 1495, 1454, 1367, 1270, 1167, 1144, 1131, 1088, 1028, 968 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.34–7.22 (m, 10H), 4.27 (m, 1H), 3.83 (d, J_{AB} = 13.6 Hz, 2H), 3.44 (d, J_{AB} = 13.6 Hz, 2H), 3.05 (ddd, J = 9.4, 4.5, 1.9 Hz, 1H), 2.60 (d, J = 6.6 Hz, 1H, OH), 1.85 (m, 1H), 1.69 (ddd, J


= 14.0, 9.5, 4.5 Hz, 1H), 1.21 (ddd, J = 14.0, 9.3, 4.9 Hz, 1H), 0.91 (d, J = 6.7 Hz, 3H), 0.51 (d, J = 6.5 Hz, 3H).

^{13}C NMR (CDCl₃, 100 MHz): δ 139.5 (2C), 129.3 (4C), 128.5 (4C), 127.4 (2C), 125.5 (q, J = 283.7 Hz), 68.0 (q, J = 29.6 Hz), 54.6 (2C), 54.4, 34.7, 24.2, 23.8, 21.5.

^{19}F NMR (CDCl₃, 376 MHz): δ – 76.09 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 365 (M⁺, 0.02), 266 (68), 181 (8), 132 (2), 91 (100), 65 (7).

(+)-(2*R*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol [(+)-*syn*-5]³



Formula: C₂₁H₂₆F₃NO **MW=** 365.44 g.mol⁻¹

[α]_D²⁵ + 23.5 (c 0.39, CHCl₃); literature: **[α]_D²⁰ + 33.4** (c 1.0, CHCl₃).

IR (neat): ν_{max} 3500, 3064, 3030, 2959, 2869, 1603, 1496, 1454, 1369, 1266, 1150, 1111, 1075, 1029, 952 cm⁻¹.

^1H NMR (CDCl₃, 400 MHz): δ 7.34–7.24 (m, 10H), 5.26 (br s, 1H, OH), 3.86 (d, J_{AB} = 13.2 Hz, 2H), 3.64 (m, 1H), 3.56 (d, J_{AB} = 13.3 Hz, 2H), 3.04 (m, 1H), 1.83 (m, 2H), 1.34 (m, 1H), 0.98 (d, J = 6.4 Hz, 3H), 0.96 (d, J = 6.4 Hz, 3H).

^{13}C NMR (CDCl₃, 100 MHz): δ 138.0 (2C), 129.2 (4C), 128.8 (4C), 127.8 (2C), 125.4 (q, J = 281.5 Hz), 70.3 (q, J = 29.5 Hz), 55.1, 54.4 (2C), 38.0, 25.8, 23.5, 22.4.

^{19}F NMR (CDCl₃, 376 MHz): δ – 75.81 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 365 (M⁺, 0.01), 266 (60), 181 (7), 132 (2), 91 (100), 65 (7).


(3*S*)-3-(Dibenzylamino)-1,1,1-trifluoro-4-methylpentan-2-ol (6)

Compound **6** was synthesized from (*S*)-2-(dibenzylamino)-3-methylbutanal **2d** (557 mg, 1.98 mmol) as a mixture of two diastereoisomers in a ratio *anti/syn* = 84:16 determined from the ^{19}F NMR spectrum of the crude. Purification by flash column chromatography (PE/EtOAc = 98:2 to 95:5) afforded (+)-*anti*-**6** (392 mg, 1.12 mmol, 56%) as a viscous yellow oil and (+)-*syn*-**6** (70.1 mg, 0.20 mmol, 10%) as a yellow oil.

For the crude:

^{19}F NMR (CDCl₃, 376 MHz): δ – 73.45 (3 x F, CF₃, *anti*), – 76.17 (3 x F, CF₃, *syn*).

(+)-(2*S*,3*S*)-3-(Dibenzylamino)-1,1,1-trifluoro-4-methylpentan-2-ol [(+)-*anti*-6]³



Formula: C₂₀H₂₄F₃NO **MW=** 351.41 g.mol⁻¹

[α]_D²⁵ + 4.6 (c 0.32, CHCl₃); literature: **[α]_D²⁰** + 3.8 (c 0.9, CHCl₃).

IR (neat): ν_{max} 3431, 3064, 3029, 2961, 2874, 2804, 1694, 1602, 1495, 1453, 1345, 1270, 1149, 1126, 1069, 1028, 971, 910 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.24 (m, 10H), 4.06 (m, 1H), 3.78 (d, *J*_{AB} = 13.4 Hz, 2H), 3.73 (d, *J*_{AB} = 13.4 Hz, 2H), 3.15 (d, *J* = 8.4 Hz, 1H, OH), 2.75 (dd, *J* = 9.6, 4.0 Hz, 1H), 2.34 (dq, *J* = 13.2, 6.5 Hz, 1H), 1.24 (d, *J* = 6.6 Hz, 3H), 0.97 (d, *J* = 6.5 Hz, 3H).


¹³C NMR (CDCl₃, 100 MHz): δ 139.2 (2C), 129.4 (4C), 128.7 (4C), 127.6 (2C), 125.7 (d_{app}, *J* = 283.6 Hz)*, 68.2 (q, *J* = 29.4 Hz), 64.6, 55.5 (2C), 27.9, 23.1, 21.3.

(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 73.07 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 351 (M⁺, 0.04), 308 (17), 252 (37), 181 (7), 91 (100), 65 (9).

(+)-(2R,3S)-3-(Dibenzylamino)-1,1,1-trifluoro-4-methylpentan-2-ol [(+)-syn-6]³



Formula: C₂₀H₂₄F₃NO **MW=** 351.41 g.mol⁻¹

[α]_D²⁵ + 13.7 (c 0.17, CHCl₃); literature: **[α]_D²⁰** + 18.2 (c 1.0, CHCl₃).

IR (neat): ν_{max} 3490, 3064, 3029, 2964, 2876, 1603, 1495, 1454, 1393, 1271, 1151, 1073, 1029, 981, 913 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.34–7.23 (m, 10H), 5.35 (br s, 1H), 4.02 (pent, *J* = 6.7 Hz, 1H), 3.91 (d, *J*_{AB} = 13.1 Hz, 2H), 3.60 (d, *J*_{AB} = 13.1 Hz, 2H), 2.86 (dd, *J* = 7.6, 4.2 Hz, 1H), 2.29 (m, 1H), 1.10 (d, *J* = 3.2 Hz, 3H), 1.09 (d, *J* = 3.3 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 137.8 (2C), 129.5 (4C), 128.8 (4C), 127.9 (2C), 125.3 (d_{app}, *J* = 281.4 Hz)*, 66.4 (q, *J* = 30.7 Hz), 61.1, 54.6 (2C), 27.1, 22.5, 19.8.

(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 76.32 (3 x F, CF₃).


MS (EI, 70 eV): *m/z* (relative intensity) = 351 (M⁺, 0.06), 308 (12), 252 (31), 181 (5), 91 (100), 65 (7).

2. Treatment with DAST

General procedure

To a stirred solution of *anti*- β -amino- α -trifluoromethyl alcohols **4-6** (1 equiv) in THF ($c = 0.095$ M) at 0 °C, was added DAST (1.4 equiv) and the resulting mixture was stirred for 1 h at 0 °C. After 2 h at rt, the reaction mixture was quenched with a saturated aqueous solution of Na_2CO_3 (5 mL), extracted with EtOAc (2 x 10 mL) and the combined organic phases were dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography to afford the desired compounds.

(–)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1,3-tetrafluoro-4-phenylbutan-2-amine [(–)-*anti*-**7**]



Formula: $\text{C}_{24}\text{H}_{23}\text{F}_4\text{N}$ **MW=** 401.45 g.mol^{–1}

Compound (–)-*anti*-**7** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (75.9 mg, 0.19 mmol). Purification by flash column chromatography (pentane/EtOAc = 98:2) afforded (–)-*anti*-**7** (66 mg, 0.16 mmol, 87%) as a viscous colorless oil.

$[\alpha]_{\text{D}}^{25} - 39.2$ (c 0.36, CHCl_3).

IR (neat): ν_{max} 3088, 3064, 3030, 2927, 2858, 1603, 1496, 1365, 1247, 1140, 1118, 1073, 1029, 971 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.34–7.19 (m, 13H), 7.08 (br d, $J = 6.5$ Hz, 2H), 4.89 (dddd, $J = 47.4, 9.3, 7.2, 3.6$ Hz, 1H), 3.92 (d, $J_{\text{AB}} = 13.6$ Hz, 2H), 3.81 (d, $J_{\text{AB}} = 13.6$ Hz, 2H), 3.34 (m, 1H), 3.21 (ddd, $J_{\text{AB}} = 35.0, 14.7, 3.6$ Hz, 1H), 2.65 (ddd, $J_{\text{AB}} = 17.1, 14.8, 9.2$ Hz, 1H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 138.3 (2C), 136.8 (d, $J = 2.7$ Hz), 129.4 (2C), 129.3 (4C), 128.76 (2C), 128.75 (4C), 127.8 (2C), 127.0, 91.3 (d, $J = 181.1$ Hz), 61.0 (qd, $J = 24.9, 22.4$ Hz), 55.3 (2C), 39.4 (d, $J = 20.9$ Hz).


CF_3 is not visible.

^{19}F NMR (CDCl_3 , 376 MHz): δ – 63.27 (d, $J = 15.2$ Hz, 3 x F, CF_3), – 191.69 (q, $J = 15.0$ Hz, F).

MS (EI, 70 eV): m/z (relative intensity) = 401 (M^{+} , 0.87), 312 (24), 278 (15), 122 (3), 91 (100), 65 (12).

HRMS: calcd for $\text{C}_{24}\text{H}_{24}\text{F}_4\text{N}$ ($\text{M}+\text{H}$)⁺ : 402.1839, found : 402.1834.

(+)-(2*S*,3*R*)-*N,N*-Dibenzyl-1,1,1,3-tetrafluoro-4-phenylbutan-2-amine [(+)-*syn*-7]



Formula: C₂₄H₂₃F₄N **MW=** 401.45 g.mol⁻¹

Compound (+)-*syn*-7 was synthesized from (2*R*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*syn*-3 (79.9 mg, 0.2 mmol). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (+)-*syn*-7 (73.3 mg, 0.18 mmol, 91%) as a colorless oil.

[α]_D²⁵ + 62.7 (*c* 0.78, CHCl₃).

IR (neat): ν_{max} 3087, 3065, 3031, 2926, 2856, 1604, 1496, 1366, 1254, 1152, 1131, 1075, 1029, 985 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.39–7.21 (m, 13H), 7.01 (br d, *J* = 6.3 Hz, 2H), 4.97 (ddt, *J* = 47.7, 8.7, 3.5 Hz, 1H), 4.19 (d, *J*_{AB} = 13.5 Hz, 2H), 3.79 (d, *J*_{AB} = 13.4 Hz, 2H), 3.30–3.16 (m, 2H), 2.56 (ddd, *J* = 33.6, 14.7, 3.6 Hz, 1H).


¹³C NMR (CDCl₃, 100 MHz): δ 139.0 (2C), 136.7 (d, *J* = 2.8 Hz), 129.43 (4C), 129.40 (2C), 128.7 (6C), 127.6 (2C), 126.9, 126.8 (q, *J* = 291.6 Hz), 92.6 (d, *J* = 181.1 Hz), 60.1 (qd, *J* = 24.7, 17.9 Hz), 56.00, 55.97, 39.1 (d, *J* = 21.5 Hz).

¹⁹F NMR (CDCl₃, 376 MHz): δ - 64.86 (d, *J* = 6.8 Hz, 3 x F, CF₃), - 191.75 (q, *J* = 6.7 Hz, F).

MS (EI, 70 eV): *m/z* (relative intensity) = 401 (M⁺, 0.44), 312 (28), 278 (17), 181 (4), 91 (100), 65 (10).

HRMS: calcd for C₂₄H₂₄F₄N (M+H)⁺ : 402.1839, found : 402.1853.

(+)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1,3-tetrafluorobutan-2-amine [(+)-8]



Formula: C₁₈H₁₉F₄N **MW=** 325.35 g.mol⁻¹

Compound (+)-8 was synthesized from (2*R*,3*R*)-*N,N*-dibenzyl-1,1,1,3-tetrafluorobutan-2-amine (+)-*anti*-4 (168 mg, 0.52 mmol). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (+)-8 (130.5 mg, 0.40 mmol, 77%) as a colorless oil.

[α]_D²⁵ + 34.8 (*c* 0.90, CHCl₃)

IR (neat): ν_{max} 3071, 3031, 2942, 2859, 1603, 1495, 1454, 1382, 1364, 1247, 1174, 1134, 1101, 1063, 1028, 977, 945 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.24 (m, 10H), 4.91 (ddq, *J* = 47.3, 7.8, 6.3 Hz, 1H), 3.94 (d, *J*_{AB} = 13.6 Hz, 2H), 3.75 (dd, *J*_{AB} = 13.6, 1.3 Hz, 2H), 3.19 (hex_{app}, *J* = 8.5 Hz, 1H), 1.36 (dd, *J* = 24.7, 6.3 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.3 (2C), 129.2 (4C), 128.7 (4C), 127.7 (2C), 127.1 (d_{app}, *J* = 292.5 Hz)*, 87.4 (d, *J* = 172.6 Hz), 62.4 (qd, *J* = 23.5, 1.2 Hz), 55.1 (2C), 19.6 (d, *J* = 22.2 Hz).


(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 63.48 (d, *J* = 15.1 Hz, 3 x F, CF₃), – 185.23 (q, *J* = 14.0 Hz, F).

MS (EI, 70 eV): *m/z* (relative intensity) = 325 (M⁺, 3), 278 (27), 234 (4), 181 (4), 91 (100), 65 (12).

HRMS: calcd for C₁₈H₂₀F₄N (M+H)⁺ : 326.1526, found : 326.1528.

(+)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1,3-tetrafluoro-5-methylhexan-2-amine [(+)-9]



Formula: C₂₁H₂₅F₄N **MW=** 367.43 g.mol⁻¹

Compound (+)-9 was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (–)-*anti*-5 (73.1 mg, 0.2 mmol). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (+)-9 (70.1 mg, 0.19 mmol, 95%) as a colorless oil.

[α]_D²⁵ + 12.6 (c 0.53, CHCl₃).

IR (neat): ν_{max} 3066, 3031, 2959, 2870, 1603, 1496, 1455, 1366, 1247, 1172, 1138, 1116, 1100, 1071, 1029, 970 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.25 (m, 10H), 4.79 (ddt, *J* = 48.7, 8.0, 2.6 Hz, 1H), 3.94 (d, *J*_{AB} = 13.5 Hz, 2H), 3.75 (d, *J*_{AB} = 13.5 Hz, 2H), 3.21 (hex_{app}, *J* = 8.5 Hz, 1H), 1.75–1.53 (m, 2H), 1.34 (m, 1H), 0.91 (t_{app}, *J* = 6.7 Hz, 6H).


¹³C NMR (CDCl₃, 100 MHz): δ 138.4 (2C), 129.3 (4C), 128.7 (4C), 127.7 (2C), 127.1 (q, *J* = 292.1 Hz), 89.5 (d, *J* = 176.7 Hz), 61.6 (qd, *J* = 24.4, 2.4 Hz), 55.2 (2C), 41.9 (d, *J* = 20.2 Hz), 24.5 (d, *J* = 2.3 Hz), 23.4, 21.8.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 63.20 (d, *J* = 15.2 Hz, 3 x F, CF₃), – 193.27 (q, *J* = 15.2 Hz, F).

MS (EI, 70 eV): *m/z* (relative intensity) = 367 (M⁺, 1), 298 (3), 278 (43), 181 (6), 91 (100), 65 (11).

HRMS: calcd for C₂₁H₂₆F₄N (M+H)⁺ : 368.1996, found : 368.1992.

(+)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1,3-tetrafluoro-4-methylpentan-2-amine [(+)-10]



Formula: C₂₀H₂₃F₄N **MW=** 353.40 g.mol⁻¹

Compound (+)-**10** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (+)-*anti*-**6** (56.2 mg, 0.16 mmol). Purification by flash column chromatography (PE 100%) afforded (+)-**10** (36.8 mg, 0.10 mmol, 66%) as a colorless oil.

[α]_D²⁵ + 7.9 (*c* 0.21, CHCl₃).

IR (neat): $\nu_{\max}$ 3065, 3031, 2967, 2935, 2859, 1603, 1495, 1455, 1366, 1248, 1140, 1116, 1093, 1072, 1029, 994, 940 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.24 (m, 10H), 4.48 (ddd, *J* = 47.2, 7.9, 3.3 Hz, 1H), 3.93 (d, *J* = 13.5 Hz, 2H), 3.75 (d, *J*_{AB} = 13.5 Hz, 2H), 3.38 (hex_{app}, *J* = 8.4 Hz, 1H), 2.10 (m, 1H), 0.91 (d, *J* = 7.1 Hz, 3H), 0.41 (dd, *J*_{AB} = 6.7, 1.0 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.5 (2C), 129.4 (4C), 128.7 (4C), 127.7 (2C), 94.4 (d, *J* = 182.1 Hz), 58.5 (qd, *J* = 23.7, 2.2 Hz), 55.1 (2C), 28.8 (d, *J* = 20.1 Hz), 19.7 (d, *J* = 3.3 Hz), 14.4 (d, *J* = 6.8 Hz).

CF₃ is not visible.

¹⁹F NMR (CDCl₃, 376 MHz): δ – 63.11 (d, *J* = 15.6 Hz, 3 x F, CF₃), – 207.9 (q, *J* = 16.3 Hz, F).

MS (EI, 70 eV): *m/z* (relative intensity) = 353 (M⁺, 1), 278 (25), 262 (10), 181 (4), 91 (100), 65 (9).

HRMS: calcd for C₂₀H₂₄F₄N (M+H)⁺: 354.1839, found: 354.1857.


3. Rearrangement of β-amino-α-trifluoromethyl alcohols

General procedure

To a stirred solution of β-amino-α-trifluoromethyl alcohols **3-6** (1.0 equiv) and proton sponge (2.1 equiv) in CH₂Cl₂ (concentration of the substrate *c* = 0.10 M) at –15 °C was added Tf₂O (1.5 equiv). After 2 h to 2.5 h of stirring, the nucleophile (Nu) was added at –15 °C and the resulting mixture was warmed to rt and stirred for 2.5 h to 4 h. The reaction mixture was diluted with H₂O (15 mL), extracted with CH₂Cl₂ (2 x 15 mL) and the combined extracts were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography to afford the desired compounds **11-14**.

a. Synthesis of β -trifluoromethyl- β -aminoalcohols

(-)-(2R,3R)-3-(Dibenzylamino)-4,4,4-trifluoro-1-phenylbutan-2-ol [(-)-*anti*-11]



Formula: $C_{24}H_{24}F_3NO$ MW= 399.46 g.mol⁻¹

Compound (-)-*anti*-11 was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-3 (79.9 mg, 0.20 mmol) using H₂O as the nucleophile (20 μ L, 1.12 mmol, 5.6 equiv). Purification by flash column chromatography (pentane/EtOAc = 95:5) afforded (-)-*anti*-11 (64.5 mg, 0.16 mmol, 81%) as a sticky colorless oil.

$[\alpha]_D^{25}$ – 44.0 (c 0.40, CHCl₃).

IR (neat): ν_{max} 3567, 3457, 3087, 3063, 3029, 2929, 2856, 1603, 1495, 1454, 1367, 1244, 1138, 1071, 1029, 970, 883 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.35 (m, 7H), 7.31–7.23 (m, 6H), 7.09–7.07 (m, 2H), 4.10 (m, 1H), 4.01 (d, J_{AB} = 13.6 Hz, 2H), 3.81 (dd, J_{AB} = 13.6, 1.3 Hz, 2H), 3.35 (dd, J_{AB} = 13.6, 2.9 Hz, 1H), 3.24 (pent_{app}, J = 8.6 Hz, 1H), 2.28 (dd, J_{AB} = 13.8, 10.0 Hz, 1H), 1.66 (d, J = 5.0 Hz, 1H, OH).

¹³C NMR (CDCl₃, 100 MHz): δ 138.6 (2C), 138.0, 129.6 (2C), 129.4 (4C), 128.9 (2C), 128.7 (4C), 127.7 (2C), 126.9, 70.6, 62.8 (q, J = 23.0 Hz), 55.4 (2C), 41.7.

CF₃ is not visible.


¹⁹F NMR (CDCl₃, 376 MHz) : δ – 62.04 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 399 (M⁺, 1), 278 (25), 91 (100), 65 (5).


HRMS: calcd for C₂₄H₂₅F₃NO (M+H)⁺ : 400.1883, found : 400.1879.

The enantiomeric excess of (-)-*anti*-11 (ee > 99%) was determined by super-critical fluid chromatography (SFC) using a chiral stationary phase (OJ-H column, P = 100 bars, flow rate = 4 mL/min, eluent = sc CO₂/MeOH = 90:10, detection at 210 nm).

($\pm$)-*anti*-11 :⁵




(-)-*anti*-11 :



⁵ Compound ($\pm$)-*anti*-11 was synthesized from ($\pm$)-*anti*-3 according to the general procedure of the rearrangement (described above).

(+)-(2*R*,3*R*)-3-(Dibenzylamino)-4,4,4-trifluorobutan-2-ol [(+)-*anti*-12]



Formula: C₁₈H₂₀F₃NO **MW=** 323.36 g.mol⁻¹

Compound (+)-*anti*-**12** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluorobutan-2-ol (+)-*anti*-**4** (100 mg, 0.31 mmol) using H₂O as the nucleophile (32 μ L, 1.75 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5 to 90:10) afforded (+)-*anti*-**12** (89.9 mg, 0.28 mmol, 89%) as a yellow solid.

mp = 77–79 °C.

[α]_D²⁵ + 42.4 (*c* 0.20, CHCl₃).

IR (neat): ν_{max} 3370, 3086, 3064, 3029, 2974, 2935, 2858, 1603, 1495, 1455, 1366, 1247, 1139, 1071, 1029, 978, 916 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.26 (m, 10H), 4.12 (hex_{app}, *J* = 7.4 Hz, 1H), 3.98 (d, *J*_{AB} = 13.5 Hz, 2H), 3.72 (dd, *J*_{AB} = 13.5, 1.4 Hz, 2H), 3.08 (pent_{app}, *J* = 8.8 Hz, 1H), 1.66 (d, *J* = 6.6 Hz, 1H, OH), 1.28 (d, *J* = 6.4 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.6 (2C), 129.3 (4C), 128.7 (4C), 127.7 (2C), 65.9, 63.9 (q, *J* = 22.6 Hz), 55.3 (2C), 21.9.


CF₃ is not visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 62.27 (3 x F, CF₃).


MS (EI, 70 eV): *m/z* (relative intensity) = 323 (*M*⁺, 1), 278 (20), 91 (100), 65 (7).

HRMS: calcd for C₁₈H₂₁F₃NO (*M*+H)⁺ : 324.1570, found : 324.1566.

Crystals suitable for X-ray diffraction analysis were obtained by slow evaporation of a solution of (+)-*anti*-**12** in PE 100% at rt. In the Supplementary Information, CCDC 1848221 corresponds to crystallographic data. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif.



(+)-(2R,3R)-2-(Dibenzylamino)-1,1,1-trifluoro-5-methylhexan-3-ol [(+)-anti-13]



Formula: C₂₁H₂₆F₃NO **MW=** 365.44 g.mol⁻¹

Compound (+)-*anti*-**13** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (–)-*anti*-**5** (73.1 mg, 0.2 mmol) using H₂O as the nucleophile (20 μL, 1.12 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5) afforded (+)-*anti*-**13** (59.7 mg, 0.163 mmol, 82%) as a white solid.

mp = 57–59 °C.

[α]_D²⁵ + 18.4 (c 0.49, CHCl₃).

IR (neat): ν_{max} 3431, 3064, 3031, 2956, 1603, 1495, 1455, 1367, 1245, 1167, 1136, 1096, 1072, 1029, 971, 915 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.24 (m, 10H), 3.97 (d, J_{AB} = 13.4 Hz, 2H), 3.95 (m, 1H), 3.73 (dd, J_{AB} = 13.5, 1.3 Hz, 2H), 3.09 (qd, J = 8.9, 1.2 Hz, 1H), 1.75 (m, 1H), 1.64 (m, 1H), 1.55 (d, J = 6.9 Hz, 1H, OH), 1.13 (ddd, J = 14.2, 10.6, 3.9 Hz, 1H), 0.90 (d, J = 5.4 Hz, 3H), 0.89 (d, J = 5.2 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.7 (2C), 129.3 (4C), 128.6 (4C), 127.6 (2C), 68.0, 63.2 (q, J = 22.4 Hz), 55.4 (2C), 44.2, 24.5, 24.0, 21.5.


CF₃ is not visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 61.93 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 365 (M⁺, 0.7), 278 (38), 181 (5), 91 (100), 65 (7).

HRMS: calcd for C₂₁H₂₇F₃NO (M+ H)⁺ : 366.2039, found : 366.2048.

(+)-((2R,3R)-2-(Dibenzylamino)-1,1,1-trifluoro-4-methylpentan-3-ol [(+)-anti-14]



Formula: C₂₀H₂₄F₃NO **MW=** 351.41 g.mol⁻¹

Compound (+)-*anti*-**14** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-methylpentan-2-ol (+)-*anti*-**6** (91.3 mg, 0.26 mmol) using H₂O as the nucleophile (27 μL, 1.47 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (+)-*anti*-**14** (48 mg, 0.136 mmol, 52%) as a colorless oil.

$[\alpha]_D^{25} + 15.9$ (c 0.54, CHCl₃).

IR (neat): $\nu_{\max}$ 3498, 3087, 3065, 3030, 2962, 2933, 2870, 1603, 1495, 1455, 1368, 1245, 1166, 1136, 1029, 969, 918 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.25 (m, 10H), 3.94 (d, J_{AB} = 13.4 Hz, 2H), 3.74 (m, 1H), 3.72 (dd, J_{AB} = 13.4, 1.2 Hz, 2H), 3.18 (pent_{app}, J = 8.8 Hz, 1H), 2.16 (m, 1H), 1.35 (d, J = 7.3 Hz, 1H, OH), 0.92 (d, J = 7.1 Hz, 3H), 0.27 (d, J = 6.8 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.7 (2C), 129.5 (4C), 128.6 (4C), 127.6 (2C), 73.8, 60.3 (q, J = 22.2 Hz), 55.1 (2C), 28.9, 20.4, 13.7.


CF₃ is not visible.

¹⁹F NMR (CDCl₃, 376 MHz): δ – 61.55 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 351 (M⁺, 0.9), 278 (34), 181 (4), 91 (100), 65 (8).

HRMS: calcd for C₂₀H₂₅F₃NO (M+H)⁺ : 352.1883, found : 352.1882.

(+)-(2R,3S)-3-(Dibenzylamino)-4,4,4-trifluoro-1-phenylbutan-2-ol [(+)-syn-11]



Formula: C₂₄H₂₄F₃NO **MW=** 399.46 g.mol⁻¹

Compound (+)-syn-11 was synthesized from (2R,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-syn-3 (107.9 mg, 0.27 mmol) using H₂O as the nucleophile (30 μ L, 1.5 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5) afforded (+)-syn-11 (96.9 mg, 0.24 mmol, 91%) as a sticky yellow oil.

$[\alpha]_D^{25} + 38.4$ (c 0.39, CHCl₃).

IR (neat): $\nu_{\max}$ 3569, 3453, 3088, 3063, 3030, 2864, 1603, 1496, 1454, 1368, 1250, 1130, 1075, 1029, 1003, 989, 968, 878 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.32–7.14 (m, 15H), 4.12 (m, 1H), 4.10 (d, J_{AB} = 13.3 Hz, 2H), 3.69 (dd, J_{AB} = 13.2, 1.2 Hz, 2H), 3.50 (s, 1H, OH), 3.12 (pent_{app}, J = 8.5 Hz, 1H), 2.90 (d, J_{AB} = 14.0 Hz, 1H), 2.54 (dd, J_{AB} = 14.1, 8.7 Hz, 1H).

¹³C NMR (CDCl₃, 100 MHz): δ 137.93, 137.86 (2C), 129.6 (2C), 129.4 (4C), 128.9 (4C), 128.4 (2C), 127.9 (2C), 127.2 (d_{app}, J = 291.6 Hz)*, 126.5, 67.1, 62.8 (q, J = 24.4 Hz), 54.7 (2C), 39.7.

(*) only the two main intense signals of the quadruplet are visible.


¹⁹F NMR (CDCl₃, 376 MHz): δ – 62.13 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 399 (M⁺, 2), 278 (26), 91 (100), 65 (6).


HRMS: calcd for C₂₄H₂₅F₃NO (M+H)⁺ : 400.1883, found : 400.1872.

The enantiomeric excess of (–)-*syn*-**11** (ee > 99%) was determined by super-critical fluid chromatography (SFC) using a chiral stationary phase (OJ-H column, P = 100 bars, flow rate = 4 mL/min, eluent = sc CO₂/MeOH = 95:5, detection at 210 nm).


(±)-*syn*-**11** :⁶



(+)-*syn*-**11** :



(–)-(2*R*,3*S*)-3-(Dibenzylamino)-4,4,4-trifluorobutan-2-ol [(–)-*syn*-**12**]



Formula: C₁₈H₂₀F₃NO **MW=** 323.36 g.mol⁻¹

Compound (–)-*syn*-**12** was synthesized from (2*R*,3*S*)-3-(dibenzylamino)-1,1,1-trifluorobutan-2-ol (+)-*syn*-**4** (74.3 mg, 0.23 mmol) using H₂O as the nucleophile (23 μL, 1.27 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5) afforded (–)-*syn*-**12** (59.3 mg, 0.18 mmol, 81%) as a yellow oil.

[α]_D²⁵ – 59.4 (c 0.16, CHCl₃).

IR (neat): ν_{max} 3450, 3065, 3030, 2974, 2935, 2865, 1603, 1496, 1455, 1369, 1250, 1169, 1130, 1093, 1075, 1028, 978, 913 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.23 (m, 10H), 4.07 (d, *J*_{AB} = 13.2 Hz, 2H), 3.96 (dq, *J* = 8.9, 6.1 Hz, 1H), 3.68 (dd, *J*_{AB} = 13.2, 1.4 Hz, 2H), 3.47 (s, 1H, OH), 2.91 (pent_{app}, *J* = 8.8 Hz, 1H), 1.17 (dd, *J* = 6.0, 1.5 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 138.0 (2C), 129.4 (4C), 128.9 (4C), 127.9 (2C), 127.0 (q, *J* = 291.3 Hz), 65.3 (q, *J* = 24.1 Hz), 62.4, 54.5 (2C), 19.1.


¹⁹F NMR (CDCl₃, 376 MHz): δ – 62.36 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 323 (M⁺, 2), 278 (36), 181 (4), 91 (100), 65 (18).

HRMS: calcd for C₁₈H₂₁F₃NO (M+H)⁺ : 324.1570, found : 324.1568.

⁶ Compound (±)-*syn*-**11** was synthesized from (±)-*syn*-**3** according to the general procedure of the rearrangement (described above).

(–)-(2S,3R)-2-(Dibenzylamino)-1,1,1-trifluoro-5-methylhexan-3-ol [(–)-*syn*-13]



Formula: C₂₁H₂₆F₃NO **MW=** 365.44 g.mol^{–1}

Compound (–)-*syn*-**13** was synthesized from (2*R*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (+)-*syn*-**5** (84 mg, 0.23 mmol) using H₂O as the nucleophile (23 μL, 1.29 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (–)-*syn*-**13** (53.3 mg, 0.146 mmol, 63%) as a colorless oil.

[α]_D²⁵ – 12.5 (c 0.36, CHCl₃).

IR (neat): ν_{max} 3451, 3067, 3032, 2958, 2871, 1605, 1498, 1457, 1369, 1280, 1167, 1132, 1105, 1073, 1031, 975, 917 cm^{–1}.

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.23 (m, 10H), 4.09 (d, J_{AB} = 13.2 Hz, 2H), 3.89 (m, 1H), 3.68 (dd, J_{AB} = 13.2, 1.3 Hz, 2H), 3.48 (s, 1H, OH), 2.96 (pent_{app}, J = 8.7 Hz, 1H), 1.81 (hept_{app}, J = 8.0 Hz, 1H), 1.25 (d, J_{AB} = 7.1 Hz, 2H), 1.21 (d, J_{AB} = 7.3 Hz, 1H), 0.867 (d, J = 6.5 Hz, 3H), 0.872 (d, J = 6.7 Hz, 3H).


¹³C NMR (CDCl₃, 100 MHz): δ 138.0 (2C), 129.4 (4C), 128.9 (4C), 127.9 (2C), 127.1 (q, J = 291.4 Hz), 64.3 (q, J = 24.0 Hz), 64.2, 54.7 (2C), 42.3, 24.5, 24.1, 21.2.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 61.90 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 365 (M⁺, 1), 278 (43), 181 (6), 91 (100), 65 (8).

HRMS: calcd for C₂₁H₂₇F₃NO (M+H)⁺ : 366.2039, found : 366.2054.

(–)-(2S,3R)-2-(Dibenzylamino)-1,1,1-trifluoro-4-methylpentan-3-ol [(–)-*syn*-14]



Formula: C₂₀H₂₄F₃NO **MW=** 351.41 g.mol^{–1}

Compound (–)-*syn*-**14** was synthesized from (2*R*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-methylpentan-2-ol (+)-*syn*-**6** (56.2 mg, 0.16 mmol) using H₂O as the nucleophile (18 μL, 0.98 mmol, 5.6 equiv). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (–)-*syn*-**14** (18 mg, 0.05 mmol, 31%) as a colorless oil.

[α]_D²⁵ – 13.2 (c 0.75, CHCl₃).

IR (neat): $\nu_{\max}$ 3429, 3091, 3066, 3033, 2965, 2935, 2874, 1605, 1498, 1457, 1369, 1251, 1164, 1131, 1076, 1031, 967, 919 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.35–7.25 (m, 10H), 4.08 (d, $J = 12.9$ Hz, 2H), 3.74 (dd, $J_{\text{AB}} = 9.1, 1.6$ Hz, 1H), 3.66 (dd, $J_{\text{AB}} = 13.0, 1.4$ Hz, 2H), 3.61 (s, 1H, OH), 3.19 (pent_{app}, $J = 8.6$ Hz, 1H), 1.74 (pent_{app}, $J = 6.7$ Hz, 1H), 0.98 (d, $J = 6.9$ Hz, 3H), 0.47 (d, $J = 6.7$ Hz, 3H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 137.8 (2C), 129.5 (4C), 128.9 (4C), 127.9 (2C), 69.2, 60.3 (q, $J = 24.4$ Hz), 54.5 (2C), 29.1, 21.0, 13.5.

CF_3 is not visible.


^{19}F NMR (CDCl_3 , 376 MHz): δ – 62.74 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 351 (M^+ , 0.5), 278 (22), 91 (100), 65 (5).

HRMS: calcd for $\text{C}_{20}\text{H}_{25}\text{F}_3\text{NO}$ ($\text{M}+\text{H}$)⁺ : 352.1883, found : 352.1876.

b. Synthesis of α -trifluoromethylamines

(–)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1-trifluoro-3-methoxy-4-phenylbutan-2-amine [(–)-15a]



Formula: $\text{C}_{25}\text{H}_{26}\text{F}_3\text{NO}$ **MW=** 413.48 $\text{g}\cdot\text{mol}^{-1}$

Compound (–)-**15a** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using anhydrous MeOH as the nucleophile (41 μL , 1.0 mmol, 5 equiv). Purification by flash column chromatography (PE 100% to PE/EtOAc = 95:5) afforded (–)-**15a** (69.5 mg, 0.17 mmol, 84%) as a viscous yellow oil.

$[\alpha]_{\text{D}}^{25}$ – 39.4 (c 0.34, CHCl_3).

IR (neat): $\nu_{\max}$ 3087, 3063, 3029, 2935, 2835, 1603, 1495, 1454, 1364, 1247, 1138, 1100, 1075, 1024, 984, 968 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.33–7.21 (m, 13H), 7.13–7.11 (m, 2H), 3.87 (d, $J_{\text{AB}} = 13.6$ Hz, 2H), 3.82 (d, $J_{\text{AB}} = 13.7$ Hz, 2H), 3.65 (m, 1H), 3.24 (dd, $J_{\text{AB}} = 13.6, 4.6$ Hz, 1H), 3.19 (dd, $J = 8.5, 7.3$ Hz, 1H), 3.04 (s, 3H), 2.48 (dd, $J_{\text{AB}} = 13.8, 8.8$ Hz, 1H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 138.69, 138.66 (2C), 129.6 (2C), 129.3 (4C), 128.7 (2C), 128.6 (4C), 127.5 (2C), 126.5, 81.2, 61.5 (q, $J = 23.5$ Hz), 59.2, 55.3 (2C), 39.6.


CF_3 is not visible.

^{19}F NMR (CDCl_3 , 376 MHz): δ – 62.73 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 413 (M^+ , 1.5), 278 (36), 135 (15), 103 (7), 91 (100), 65 (7).

HRMS: calcd for $\text{C}_{25}\text{H}_{26}\text{F}_3\text{NONa}$ ($\text{M}+\text{Na}$)⁺ : 436.1859, found : 436.1840.

(–)-(2R,3R)-3-(Allyloxy)-N,N-dibenzyl-1,1,1-trifluoro-4-phenylbutan-2-amine [(–)-15b]



Formula: C₂₇H₂₈F₃NO **MW=** 439,52 g.mol^{–1}

Compound (–)-**15b** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using allylic alcohol as the nucleophile (70 μ L, 1.0 mmol, 5 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5) afforded (–)-**15b** (61.5 mg, 0.14 mmol, 70%) as a colorless oil.

[α]_D²⁵ – 32.3 (*c* 0.19, CHCl₃).

IR (neat): ν_{max} 3086, 3063, 3029, 2925, 2856, 1603, 1544, 1495, 1328, 1188, 1137, 1074, 1027, 989, 970, 921 cm^{–1}.

¹H NMR (CDCl₃, 400 MHz): δ 7.34–7.19 (m, 13H), 7.13–7.11 (m, 2H), 5.62 (m, 1H), 5.04–4.99 (m, 2H), 3.91 (d, *J*_{AB} = 13.5 Hz, 2H), 3.81 (d, *J*_{AB} = 13.1 Hz, 2H), 3.80 (m, 1H), 3.71 (dd, *J*_{AB} = 11.5, 5.8 Hz, 1H), 3.41 (dd, *J*_{AB} = 11.5, 6.0 Hz, 1H), 3.32 (dd, *J*_{AB} = 13.9, 3.9 Hz, 1H), 3.24 (pent_{app}, *J* = 8.2 Hz, 1H), 2.44 (dd, *J*_{AB} = 13.8, 9.1 Hz, 1H).


¹³C NMR (CDCl₃, 100 MHz): δ 138.8, 138.6 (2C), 134.1, 129.7 (2C), 129.3 (4C), 128.6 (6C), 127.7 (q, *J* = 292.7 Hz), 127.6 (2C), 126.6, 117.4, 79.2, 72.9, 61.8 (q, *J* = 23.2 Hz), 55.3 (2C), 40.1.

¹⁹F NMR (CDCl₃, 376 MHz): δ – 62.23 (3 $\times$ F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 439 (M⁺, 0.35), 278 (32), 197 (10), 143 (13), 91 (100), 65 (7).

HRMS: calcd for C₂₇H₂₉F₃NO (M+H)⁺ : 440.2196, found : 440.2193.

(–)-(2R,3R)-N,N-Dibenzyl-1,1,1-trifluoro-3-phenoxy-4-phenylbutan-2-amine [(–)-15c]



Formula: C₃₀H₂₈F₃NO **MW=** 475.56 g.mol^{–1}

Compound (–)-**15c** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (59.9 mg, 0.15 mmol) using dry NaOPh as the nucleophile (44 mg, 0.38 mmol, 2.5 equiv). Purification by flash column chromatography (PE/EtOAc = 98:2) afforded (–)-**15c** (53.7 mg, 0.11 mmol, 75%) as a sticky colorless oil.

$[\alpha]_D^{25} - 22.4$ (c 0.25, CHCl_3).

IR (neat): ν_{max} 3089, 3065, 3031, 2930, 2857, 2812, 1600, 1590, 1496, 1456, 1366, 1239, 1142, 1112, 1076, 1004, 973, 922 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.30–7.14 (m, 15H), 7.07–7.05 (m, 2H), 6.87 (t_{app} , $J = 7.3$ Hz, 1H), 6.69 (d, $J = 7.9$ Hz, 2H), 4.77 (q_{app} , $J = 5.9$ Hz, 1H), 3.87 (d, $J_{\text{AB}} = 13.6$ Hz, 2H), 3.71 (d, $J_{\text{AB}} = 13.6$ Hz, 2H), 3.43 (m, 1H), 3.25 (dd, $J_{\text{AB}} = 14.0$, 6.5 Hz, 1H), 2.88 (dd, $J_{\text{AB}} = 14.0$, 7.0 Hz, 1H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 157.6, 138.6 (2C), 137.3, 129.8 (2C), 129.5 (2C), 129.2 (4C), 128.8 (2C), 128.6 (4C), 127.5 (2C), 126.9, 121.3, 115.6 (2C), 76.8, 60.7 (q, $J = 24.4$ Hz), 55.4 (2C), 38.8.


CF_3 is not visible.

^{19}F NMR (CDCl_3 , 376 MHz): $\delta - 63.10$ (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 475 (M^+ , 0.01), 382 ($[\text{M}^+ - \text{OPh}]$, 20), 278 (26), 119 (4), 91 (100), 65 (5).

HRMS: calcd for $\text{C}_{30}\text{H}_{29}\text{F}_3\text{NO}$ ($\text{M}+\text{H}$) $^+$: 476.2196, found: 476.2186.

(–)-Benzyl-*N*-[(2*R*,3*R*)-3-(dibenzylamino)-4,4,4-trifluoro-1-phenylbutan-2-yl]-L-prolinate [(–)-15d]



Formula: $\text{C}_{36}\text{H}_{37}\text{F}_3\text{N}_2\text{O}_2$ **MW=** 586.70 $\text{g}\cdot\text{mol}^{-1}$

Compound (–)-**15d** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using L-proline benzyl ester as the nucleophile (103 mg, 0.5 mmol, 2.5 equiv). Purification by flash column chromatography (PE/EtOAc = 98:2 to 95:5) afforded (–)-**15d** (80 mg, 0.13 mmol, 68%) as a colorless sticky oil.

$[\alpha]_D^{25} - 28.9$ (c 0.38, CHCl_3).

IR (neat): ν_{max} 3063, 3029, 2947, 2864, 1742, 1602, 1495, 1454, 1367, 1241, 1157, 1132, 1105, 1075, 1029, 996, 970, 908 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.33–7.14 (m, 20H), 5.01 (d, $J_{\text{AB}} = 12.4$ Hz, 1H), 4.96 (d, $J_{\text{AB}} = 12.4$ Hz, 1H), 4.00–3.89 (m, 3H), 3.69 (d, $J_{\text{AB}} = 13.4$ Hz, 2H), 3.47 (dd, $J_{\text{AB}} = 14.4$, 2.9 Hz, 1H), 3.16 (dq, $J = 16.3$, 8.1 Hz, 1H), 2.80 (dd, $J = 8.9$, 3.1 Hz, 1H), 2.72 (m, 1H), 2.60 (td, $J = 7.3$, 2.0 Hz, 1H), 2.39 (dd, $J_{\text{AB}} = 14.4$, 10.9 Hz, 1H), 1.79 (m, 1H), 1.71–1.57 (m, 2H), 1.23 (m, 1H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 173.6, 140.5, 138.8 (2C), 136.3, 129.54 (4C), 129.49 (2C), 128.63 (2C), 128.58 (4C), 125.51 (2C), 128.2 (2C), 128.1, 127.5 (2C), 126.4, 66.2, 63.9, 61.8 (q, $J = 21.6$ Hz), 58.4, 54.9 (2C), 44.5, 34.3, 28.6, 25.0.


CF_3 is not visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 62.86 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 451 ([M⁺ – •CO₂Bn], 1), 308 (100), 217 (7), 172 (9), 104 (8), 91 (67).

HRMS: calcd for C₃₆H₃₇F₃N₂O₂Na (M+Na)⁺ : 609.2699, found : 609.2696.

(–)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1-trifluoro-3-morpholino-4-phenylbutan-2-amine [(–)-15e]



Formula: C₂₈H₃₁F₃N₂O **MW=** 468.56 g.mol^{–1}

Compound (–)-**15e** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (59.9 mg, 0.15 mmol) using morpholine as the nucleophile (38 μ L, 0.42 mmol, 2.8 equiv). Purification by flash column chromatography (PE 100% and PE/EtOAc = 95:5) afforded (–)-**15e** (57 mg, 0.12 mmol, 80%) as a pale pink solid.

mp = 101–103 °C.

[α]_D²⁵ – 12.4 (*c* 0.48, CHCl₃).

IR (neat): $\nu_{\max}$ 3086, 3062, 3028, 2951, 2856, 1683, 1602, 1495, 1265, 1156, 1132, 1115, 1075, 997, 970, 912 cm^{–1}.

¹H NMR (CDCl₃, 400 MHz): δ 7.33–7.16 (m, 15H), 4.05 (br d, J_{AB} = 11.5 Hz, 2H), 3.79 (d, J_{AB} = 13.4 Hz, 2H), 3.48–3.43 (m, 3H), 3.40–3.28 (m, 3H), 3.18 (pent_{app}, J = 8.5 Hz, 1H), 2.43–2.33 (m, 3H), 2.19–2.14 (m, 2H).

¹³C NMR (CDCl₃, 100 MHz): δ 141.0 (2C), 138.7, 129.4 (2C), 129.3 (4C), 128.8 (2C), 128.7 (4C), 128.3 (d_{app}, J = 293.3 Hz)*, 127.6 (2C), 126.3, 67.5 (2C), 64.8, 61.0 (q, J = 20.9 Hz), 55.1 (2C), 50.0 (2C), 34.4.


(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 61.57 (3 x F, CF₃).

MS (EI, 70 eV): m/z (relative intensity) = 377 ([M⁺ – •Bn], 0.1), 190 (100), 91 (24).

HRMS: calcd for C₂₈H₃₂F₃N₂O (M+H)⁺: 469.2461, found : 469.2443.

(+)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1-trifluoro-*N'*,4-diphenylbutane-2,3-diamine [(+)-15f]



Formula: C₃₀H₂₉F₃N₂ **MW=** 474.57 g.mol⁻¹

Compound (+)-**15f** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using PhNH₂ as the nucleophile (50 μ L, 0.55 mmol, 2.7 equiv). Purification by flash column chromatography (PE/EtOAc = 95:5) afforded (+)-**15f** (90 mg, 0.19 mmol, 95%) as a sticky yellow oil.

[α]_D²⁵ + 3.1 (*c* 0.65, CHCl₃).

IR (neat): ν_{max} 3405, 3087, 3062, 3028, 2927, 2855, 1601, 1496, 1454, 1366, 1323, 1244, 1133, 1097, 1074, 1028, 970, 919 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.31–7.17 (m, 13H), 7.07–7.05 (m, 2H), 6.94 (dd, *J* = 6.5, 2.9 Hz, 2H), 6.64 (t_{app}, *J* = 7.3 Hz, 1H), 6.40 (d, *J* = 7.8 Hz, 2H), 4.02 (m, 1H), 3.88 (d, *J*_{AB} = 13.7 Hz, 2H), 3.83 (d, *J*_{AB} = 13.7 Hz, 2H), 3.57 (d, *J* = 10.9 Hz, 1H, NH), 3.34 (m, 1H), 3.07 (dd, *J*_{AB} = 13.6, 6.7 Hz, 1H), 2.80 (dd, *J*_{AB} = 13.6, 6.9 Hz, 1H).

¹³C NMR (CDCl₃, 100 MHz): δ 146.6, 138.8 (2C), 138.0, 129.6 (2C), 129.4 (2C), 129.3 (4C), 128.7 (2C), 128.6 (4C), 127.5 (2C), 126.7, 117.8, 113.5 (2C), 60.5 (q, *J* = 23.3 Hz), 55.5 (2C), 54.0, 39.3.


CF₃ is not visible.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 62.77 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 474 (M⁺, 0.16), 259 (11), 196 (100), 118 (12), 104 (8), 91 (38).

HRMS: calcd for C₃₀H₃₀F₃N₂ (M+H)⁺ : 475.2356, found : 475.2353.

(+)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1-trifluoro-4-phenyl-3-(1*H*-pyrazol-1-yl)butan-2-amine [(+)-15g]




Formula: C₂₇H₂₆F₃N₃ **MW=** 449.52 g.mol⁻¹

Compound (+)-**15g** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (59.9 mg, 0.15 mmol) using sodium 1*H*-pyrazolide as the nucleophile (0.5 M in THF) (0.9 mL,

MS (EI, 70 eV): m/z (relative intensity) = 382 ($[M^{+} - ^\bullet\text{SEt}]$, 13), 278 (33), 181 (4), 91 (100), 65 (6).

HRMS: calcd for $\text{C}_{26}\text{H}_{28}\text{F}_3\text{NSNa}$ ($M+\text{Na}$) $^{+}$: 466.1787, found : 466.1766.

(–)-(2*S*,3*R*)-*N,N*-Dibenzyl-3-bromo-1,1,1-trifluoro-4-phenylbutan-2-amine [(–)-15i]



Formula: $\text{C}_{24}\text{H}_{23}\text{BrF}_3\text{N}$ **MW=** 462.35 g.mol $^{-1}$

Compound (–)-**15i** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using dry $n\text{-Bu}_4\text{NBr}$ as the nucleophile (195.4, 0.6 mmol, 3 equiv). Purification by flash column chromatography (PE 100% and PE/EtOAc = 95:5) afforded (–)-**15i** (74 mg, 0.16 mmol, 80%) as a pale green oil.

$[\alpha]_D^{25}$ – 32.9 (c 2.47, CHCl_3).

IR (neat): ν_{max} 3089, 3066, 3032, 2926, 2859, 1605, 1498, 1456, 1369, 1252, 1127, 1103, 1076, 1031, 969 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.34–7.25 (m, 13H), 7.07 (dd_{app}, J = 7.4, 1.9 Hz, 2H), 4.25 (ddd, J = 10.5, 6.6, 4.7 Hz, 1H), 3.96 (d, J_{AB} = 13.6 Hz, 2H), 3.88 (d, J_{AB} = 13.6 Hz, 2H), 3.72 (dd, J_{AB} = 14.6, 4.6 Hz, 1H), 3.55 (m, 1H), 2.72 (dd, J_{AB} = 14.6, 10.2 Hz, 1H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 138.24, 138.2 (2C), 129.3 (6C), 128.8 (2C), 128.7 (4C), 127.8 (2C), 127.1, 126.7 (d_{app}, J = 291.2 Hz)*, 63.0 (q, J = 24.7 Hz), 55.3 (2C), 49.4, 43.3.


(*) only the two main intense signals of the quadruplet are visible.

^{19}F NMR (CDCl_3 , 376 MHz) : δ – 62.02 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 462 (M^{+} , 0.02), 382 ($[M^{+} - ^\bullet\text{Br}]$, 27), 278 (4), 196 (8), 185 (13), 91 (100).

HRMS: calcd for $\text{C}_{24}\text{H}_{24}^{19}\text{BrF}_3\text{N}$ ($M+\text{H}$) $^{+}$: 462.1039, found : 462.1029 and calcd for $\text{C}_{24}\text{H}_{24}^{18}\text{BrF}_3\text{N}$ ($M+\text{H}$) $^{+}$: 464.1018, found : 464.1007.

(–)-(R)-N,N-Dibenzyl-1,1,1-trifluoro-4-phenylbutan-2-amine [(–)-15j]



Formula: C₂₄H₂₄F₃N **MW=** 383.46 g.mol^{–1}

Compound (–)-**15j** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using *n*-Bu₄NBH₄ as the nucleophile (131.3 mg, 0.5 mmol, 2.5 equiv). Purification by flash column chromatography (EP/EtOAc 98:2) afforded (–)-**15j** (69 mg, 0.18 mmol, 90%) as a brown oil.

[α]_D²⁵ – 30.9 (c 0.48, CHCl₃).

IR (neat): ν_{max} 3064, 3029, 2956, 2858, 1603, 1495, 1454, 1371, 1250, 1140, 1102, 1073, 1029, 969 cm^{–1}.

¹H NMR (CDCl₃, 400 MHz): δ 7.35–7.14 (m, 13H), 7.01 (br d, *J* = 7.0 Hz, 2H), 3.96 (d, *J*_{AB} = 13.6 Hz, 2H), 3.71 (dd, *J*_{AB} = 13.6, 1.3 Hz, 2H), 3.16 (m, 1H), 2.91 (ddd, *J*_{AB} = 14.6, 10.4, 5.6 Hz, 1H), 2.41 (ddd, *J*_{AB} = 13.9, 10.1, 6.4 Hz, 1H), 2.00 (m, 1H), 1.87 (m, 1H).

¹³C NMR (CDCl₃, 100 MHz): δ 141.4, 139.2 (2C), 129.2 (4C), 128.61 (2C), 128.58 (4C), 128.5 (2C), 128.1 (d_{app}, *J* = 291.5 Hz)*, 127.4 (2C), 126.2, 58.1 (q, *J* = 24.8 Hz), 54.3 (2C), 32.7, 28.6.


(*) only the two main intense signals of the quadruplet are visible.

¹⁹F NMR (CDCl₃, 376 MHz): δ – 67.72 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 383 (M⁺, 7), 314 (21), 292 (27), 188 (6), 91 (100), 65 (10).

HRMS: calcd for C₂₄H₂₅F₃N (M+H)⁺ : 384.1934, found : 384.1934.

(–)-(2R,3R)-N,N,3-Tribenzyl-1,1,1-trifluoroheptan-2-amine [(–)-15k]



Formula: C₂₈H₃₂F₃N **MW=** 439.57 g.mol^{–1}

Compound (–)-**15k** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (79.9 mg, 0.20 mmol) using *n*BuCu(CN)Li as the nucleophile (0.15 M/Et₂O) (5 mL, 0.74 mmol, 3.7 equiv). Purification by flash column chromatography (PE 100%) afforded (–)-**15k** (52.9 mg, 0.12 mmol, 60%) as a cloudy colorless oil.

$[\alpha]_D^{25} = -6.9$ (c 0.47, CHCl_3).

IR (neat): ν_{max} 3062, 3028, 2957, 2861, 1603, 1496, 1454, 1367, 1242, 1134, 1091, 1073, 1029, 968, 913 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.24–7.07 (m, 13H), 6.98 (d_{app} , $J = 7.0$ Hz, 2H), 3.87 (d, $J_{\text{AB}} = 13.5$ Hz, 2H), 3.68 (dd, $J_{\text{AB}} = 13.5$, 0.7 Hz, 2H), 3.19–3.11 (m, 2H), 2.21 (dd, $J = 13.5$, 10.5 Hz, 1H), 2.01 (m, 1H), 1.26 (m, 1H), 1.12 (m, 1H), 1.01–0.85 (m, 2H), 0.74–0.68 (m, 2H), 0.60 (t, $J = 7.3$ Hz, 3H).

^{13}C NMR (CDCl_3 , 100 MHz): δ 141.0, 139.1 (2C), 129.4 (4C), 129.3 (2C), 128.5 (6C), 127.4 (2C), 126.1, 59.6 (q, $J = 23.3$ Hz), 55.5 (2C), 39.3, 37.0, 28.3, 27.7, 22.8, 13.9.


CF_3 is not visible.

^{19}F NMR (CDCl_3 , 376 MHz): δ – 63.15 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 439 (M^+ , 5), 348 (13), 278 (29), 188 (4), 91 (100), 65 (6).

HRMS: calcd for $\text{C}_{28}\text{H}_{33}\text{F}_3\text{N}$ ($\text{M}+\text{H}$) $^+$: 440.2560, found: 440.2559.

(–)-(2R,3R)-2-Benzyl-3-(dibenzylamino)-4,4,4-trifluorobutanenitrile [(–)-15I]



Formula: $\text{C}_{25}\text{H}_{23}\text{F}_3\text{N}_2$ **MW=** 408.47 $\text{g}\cdot\text{mol}^{-1}$

Compound (–)-**15I** was synthesized from (2S,3S)-3-(dibenzylamino)-1,1,1-trifluoro-4-phenylbutan-2-ol (+)-*anti*-**3** (59.9 mg, 0.15 mmol) using dry *n*- Bu_4NCN as the nucleophile (120 mg, 0.42 mmol, 2.9 equiv). Purification by flash column chromatography (EP/EtOAc 95:5) afforded (–)-**15I** (36.6 mg, 0.089 mmol, 60%) as a yellow oil.

$[\alpha]_D^{25} = -41.0$ (c 0.61, CHCl_3).

IR (neat): ν_{max} 3064, 3031, 2933, 2861, 1603, 1496, 1455, 1369, 1247, 1143, 1128, 1103, 1075, 1028, 970 cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ 7.37–7.25 (m, 13H), 7.10–7.07 (m, 2H), 3.92 (d, $J_{\text{AB}} = 13.5$ Hz, 2H), 3.83 (d, $J_{\text{AB}} = 13.5$ Hz, 2H), 3.42 (pent_{app} , $J = 8.1$ Hz, 1H), 3.27 (dd, $J_{\text{AB}} = 13.7$, 5.3 Hz, 1H), 3.05 (ddd, $J = 10.1$, 7.7, 5.3 Hz, 1H), 2.58 (dd, $J_{\text{AB}} = 13.7$, 10.2 Hz, 1H).


^{13}C NMR (CDCl_3 , 100 MHz): δ 137.6 (2C), 136.3, 129.20 (4C), 129.15 (2C), 129.1 (2C), 128.9 (4C), 128.0 (2C), 127.7, 126.4 (q, $J = 291.5$ Hz), 118.5, 60.2 (q, $J = 26.0$ Hz), 54.8 (2C), 36.6, 32.8.

^{19}F NMR (CDCl_3 , 376 MHz): δ – 64.05 (3 x F, CF_3).

MS (EI, 70 eV): m/z (relative intensity) = 408 (M^+ , 0.6), 278 (18), 91 (100), 65 (6).

HRMS: calcd for $\text{C}_{25}\text{H}_{23}\text{F}_3\text{N}_2\text{Na}$ ($\text{M}+\text{Na}$) $^+$: 431.1706, found: 431.1704.

(–)-(2*R*,3*R*)-*N,N*-Dibenzyl-1,1,1-trifluoro-5-methyl-3-phenoxyhexan-2-amine [(–)-16]



Formula: C₂₇H₃₀F₃NO **MW=** 441.54 g.mol⁻¹

Compound (–)-**16** was synthesized from (2*S*,3*S*)-3-(dibenzylamino)-1,1,1-trifluoro-5-methylhexan-2-ol (–)-*anti*-**5** (174 mg, 0.476 mmol) using dry NaOPh as the nucleophile (139.4 mg, 1.19 mmol, 2.5 equiv). Purification by flash column chromatography (PE/EtOAc = 99:1) afforded (–)-**16** (148.9 mg, 0.34 mmol, 71%) as a colorless oil.

[α]_D²⁵ – 31.0 (*c* 0.39, CHCl₃).

IR (neat): ν_{max} 3064, 3030, 2957, 2869, 1598, 1493, 1455, 1368, 1238, 1135, 1097, 1074, 1028, 971 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.32–7.20 (m, 12H), 6.90 (tt_{app}, *J* = 1.0, 0.8 Hz, 1H), 6.84–6.82 (m, 2H), 4.69 (dt_{app}, *J* = 7.5, 5.5 Hz, 1H), 3.95 (d, *J*_{AB} = 13.6 Hz, 2H), 3.81 (dd, *J*_{AB} = 13.6, 1.0 Hz, 2H), 3.42 (m, 1H), 1.76 (m, 1H), 1.57–1.40 (m, 2H), 0.82 (d, *J* = 6.5 Hz, 3H), 0.81 (d, *J* = 6.5 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 158.1, 138.7 (2C), 129.6 (2C), 129.3 (4C), 128.6 (4C), 127.6 (2C), 127.4 (q, *J* = 292.1 Hz), 121.0, 115.3 (2C), 74.2, 61.2 (q, *J* = 23.7 Hz), 55.5 (2C), 41.8, 24.3, 23.4, 22.6.


¹⁹F NMR (CDCl₃, 376 MHz): δ – 62.44 (3 × F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 441 (M⁺, 0.4), 278 (64), 107 (8), 91 (100), 69 (9), 65 (8).

HRMS: calcd for C₂₇H₃₁F₃NO (M+H)⁺: 442.2352, found: 442.2350.

4. Application of α -trifluoromethylamines

(+)-(2*R*,3*R*)-1,1,1-Trifluoro-5-methyl-3-phenoxyhexan-2-amine [(+)-**17**]



Formula: C₁₃H₁₈F₃NO **MW=** 261.29 g.mol⁻¹

To a stirred solution of (2*R*,3*R*)-*N,N*-dibenzyl-1,1,1-trifluoro-5-methyl-3-phenoxyhexan-2-amine (–)-**16** (99.2 mg, 0.22 mmol, 1.0 equiv) in anhydrous methanol, 10% Pd/C (20 mol %) was added. The mixture was stirred under hydrogen pressure (1 atm) at rt for 4 days. The mixture was then filtered over a Celite pad, washed with methanol and CH₂Cl₂ and concentrated under reduced pressure. Purification by flash column chromatography (PE/EtOAc = 99:1 then 95:5) afforded (+)-**17** (35.6 mg, 0.14 mmol, 61%) as a colorless oil.

[α]_D²⁵ + 38.7 (*c* 0.47, CHCl₃).

IR (neat): $\nu_{\max}$ 3350, 2959, 1597, 1493, 1268, 1228, 1165, 1133, 1115, 992, 958 cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ 7.33–7.25 (m, 2H), 7.00–6.93 (m, 3H), 4.64 (dt, *J* = 9.9, 2.6 Hz, 1H), 3.62 (qd, *J* = 8.3, 2.8 Hz, 1H), 1.90–1.82 (m, 2H), 1.52 (br s, 2H, NH₂), 1.39 (m, 1H), 0.98 (d, *J* = 6.5 Hz, 3H), 0.91 (d, *J* = 6.5 Hz, 3H).


¹³C NMR (CDCl₃, 100 MHz): δ 157.5, 131.0 (q, *J* = 261.7 Hz), 130.0 (2C), 121.8, 116.0 (2C), 73.9, 55.1 (q, *J* = 27.3 Hz), 37.8, 24.5, 23.7, 21.8.

¹⁹F NMR (CDCl₃, 376 MHz): δ – 73.61 (3 x F, CF₃).

MS (EI, 70 eV): *m/z* (relative intensity) = 261 (M⁺, 14), 163 (100), 121 (33), 107 (78), 98 (54), 69 (97).

HRMS: calcd for C₁₃H₁₉F₃NO (M+H)⁺ : 262.1413, found : 262.1414.

(–)-Benzyl-((S)-1-oxo-1-{[(2R,3R)-1,1,1-trifluoro-5-methyl-3-phenoxyhexan-2-yl]amino}-propan-2-yl)carbamate [(–)-18]



Formula: C₂₄H₂₉F₃N₂O₄ **MW=** 466.50 g.mol^{–1}

Compound (–)-**18** was prepared according to a described procedure.⁷ To a stirred solution of *N*-CBz-L-Alanine (28.3 mg, 0.124 mmol, 1.0 equiv) in anhydrous ethyl acetate (1.25 mL) at –15 °C, were added *N*-methylmorpholine (15.3 µL, 0.137 mmol, 1.1 equiv) and isobutyl chloroformate (18.2 µL, 0.137 mmol, 1.1 equiv). After 30 min, a solution of (2*R*,3*R*)-1,1,1-trifluoro-5-methyl-3-phenoxyhexan-2-amine (+)-**17** (32.8 mg, 0.124 mmol, 1.0 equiv) in anhydrous EtOAc (0.7 mL) was added, the resulting mixture was stirred at – 15 °C for 1 h and then warmed to rt before stirring for 14 h. The reaction mixture was extracted with the following order: H₂O (x 2), a 10 % aqueous solution of citric acid (x 2), H₂O (x 2), a saturated aqueous solution of NaHCO₃ (x 2) and H₂O (x 2). The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. Purification by flash column chromatography (PE/EtOAc = 95:5 to 80:20) afforded (–)-**18** (33.6 mg, 0.072 mmol, 58%) as a colorless oil.

[α]_D²⁵ – 19.2 (c 0.10, CHCl₃).

IR (neat): $\nu_{\max}$ 3292, 3067, 3036, 2958, 2873, 1672, 1597, 1588, 1533, 1493, 1330, 1224, 1180, 1150, 1112, 1073, 1028, 996, 952 cm^{–1}.

¹H NMR (CDCl₃, 400 MHz): δ 7.37–7.25 (m, 7H), 6.99 (t_{app}, *J* = 7.4 Hz, 1H), 6.91 (d, *J* = 7.8 Hz, 2H), 6.88 (m, 1H), 5.28 (d, *J* = 5.2 Hz, 1H), 5.08–5.01 (m, 2H), 4.94 (m, 1H), 4.60 (m, 1H), 4.30 (m, 1H), 1.87–1.74 (m, 2H), 1.49 (m, 1H), 1.36 (d, *J* = 7.1 Hz, 3H), 0.97 (d, *J* = 6.6 Hz, 3H), 0.93 (d, *J* = 6.5 Hz, 3H).

¹³C NMR (CDCl₃, 100 MHz): δ 172.5, 157.6, 156.4, 136.0, 130.0 (2C), 128.7 (2C), 128.4, 128.2 (2C), 124.4 (q, *J* = 282.9 Hz), 122.3, 116.5 (2C), 74.5, 67.4, 52.5 (q, *J* = 28.9 Hz), 50.6, 39.2, 24.5, 23.4, 22.1, 17.9.

¹⁹F NMR (CDCl₃, 376 MHz) : δ – 70.49 (3 x F, CF₃).


MS (EI, 70 eV): *m/z* (relative intensity) = 466 (M⁺, 0.2), 373 (25), 163 (19), 107 (16), 91 (100), 69 (18).

HRMS: calcd for C₂₄H₂₉F₃N₂O₄ (M+Na)⁺: 489.1972, found : 489.1970.


⁷ Kokschi, B.; Sewald, N.; Hofmann, H.-J.; Burger, K.; Jakubke, H.-D. *J. Pept. Sci.* **1997**, *3*, 157–167.

ALDEHYDES


^1H NMR, 400 MHz, CDCl_3




^{13}C NMR, 100 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃



¹H NMR, 400 MHz, CDCl₃





¹³C NMR, 100 MHz, CDCl₃




β -AMINO- α -TRIFLUOROMETHYL ALCOHOLS


Crude of 3: ^{19}F NMR, 376 MHz, CDCl_3

¹H NMR, 400 MHz, CDCl₃

¹³C NMR, 100 MHz, CDCl₃



¹⁹F NMR, 376 MHz, CDCl₃



Chemical structure of (+)-*syn*-3 is shown. The ^1H NMR spectrum (CDCl₃) displays peaks corresponding to the structure, with integration values indicated below the peaks.


Chemical structure of (+)-*syn*-3 is shown in the top left. The ¹³C NMR spectrum (CDCl₃) is displayed below, with peaks labeled in ppm. Two insets provide expanded views of the aromatic region (126-130 ppm) and the aliphatic region (69-70 ppm).

Chemical Structure: (+)-*syn*-3 is a chiral molecule with a central carbon atom bonded to a phenyl group, a hydroxyl group, a trifluoromethyl group, and a chiral auxiliary group.


13C NMR Spectrum (CDCl₃):

- Aromatic Region (126-130 ppm):** Peaks are observed at 129.48, 128.72, 128.58, 127.77, and 127.03 ppm.
- Aliphatic Region (69-70 ppm):** Peaks are observed at 69.85, 69.55, 69.26, and 69.04 ppm.
- Other Peaks:** Additional peaks are labeled at 139.07, 137.70, 129.48, 128.72, 128.58, 127.77, 127.03, 77.48, 76.84, 75.70, 69.85, 69.55, 69.26, 69.04, 57.98, 54.20, and 34.52 ppm.


¹⁹F NMR, 376 MHz, CDCl₃




Crude of 4: ^{19}F NMR, 376 MHz, CDCl_3




^1H NMR, 400 MHz, CDCl_3




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




Crude of 5: ^{19}F NMR, 376 MHz, CDCl_3




^1H NMR, 400 MHz, CDCl_3




^{13}C NMR, 100 MHz, CDCl_3




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




Crude of 6: ^{19}F NMR, 376 MHz, CDCl_3




^1H NMR, 400 MHz, CDCl_3 [contains a trace of (+)-syn-6]




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃ [contains a trace of (+)-*syn*-6]




¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃ [contains a trace of (+)-*anti*-6]




β-FLUORO-α-TRIFLUOROMETHYLAMINE DERIVATIVES


¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




β-TRIFLUOROMETHYL-β-AMINOALCOHOL DERIVATIVES


¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃




Chemical structure of (-)-anti-11 is shown. The structure is a secondary amine with a benzyl group, a 2-(benzyloxy)-2-methylpropan-1-yl group, and a 2-(benzyloxy)-2-methylpropan-1-yl group. The stereochemistry is indicated as (-)-anti-11.




1H NMR spectrum (CDCl₃) of (-)-anti-11. The x-axis represents the chemical shift in ppm, ranging from 20 to -220. A single sharp peak is visible at approximately -62.04 ppm, corresponding to the solvent CDCl₃. The rest of the spectrum is flat, indicating no other significant peaks are present in this range.


¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃



¹⁹F NMR, 376 MHz, CDCl₃



Chemical structure of (+)-*anti*-13 is shown. The structure features a central chiral center with a hydroxyl group (OH), a trifluoromethyl group (CF₃), and two benzyl groups. The stereochemistry is indicated as (+)-*anti*.

¹H NMR spectrum (CDCl₃) of (+)-*anti*-13. The spectrum shows peaks corresponding to the structure, with chemical shifts (f1) in ppm and integration values provided.


Chemical shifts (f1) in ppm: 7.36, 7.35, 7.34, 7.33, 7.32, 7.31, 7.30, 7.29, 7.28, 7.27, 7.26, 7.25, 3.99, 3.96, 3.94, 3.93, 3.75, 3.74, 3.71, 3.14, 3.12, 3.10, 3.09, 3.07, 3.05, 1.78, 1.77, 1.76, 1.75, 1.74, 1.73, 1.72, 1.71, 1.68, 1.67, 1.66, 1.65, 1.64, 1.63, 1.62, 1.61, 1.56, 1.54, 1.17, 1.16, 1.15, 1.14, 1.13, 1.12, 1.11, 1.10, 0.91, 0.90, 0.89, 0.88.

Integration values: 9.87, 2.85, 1.89, 0.93, 0.97, 1.02, 1.13, 1.02, 1.02, 2.83, 2.70.


Chemical structure of (+)-*anti*-13 is shown. The structure features a central carbon atom bonded to a hydroxyl group (OH), a phenyl ring, a trifluoromethyl group (CF₃), and a side chain containing a benzyl group and a phenyl ring. The stereochemistry is indicated as (+)-*anti*-13.

¹³C NMR spectrum (CDCl₃) of (+)-*anti*-13. The spectrum shows peaks corresponding to the chemical structure, including aromatic carbons (127-139 ppm), the CDCl₃ solvent triplet (77 ppm), and aliphatic carbons (21-55 ppm). The inset shows the region from 62 to 64 ppm, highlighting the CDCl₃ solvent triplet and the CDCl₃ solvent triplet.


¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃ [contains one impurity (*)]




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃ [contains some impurities (*)]




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃ [contains some impurities (*)]




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




^1H NMR, 400 MHz, CDCl_3




^{13}C NMR, 100 MHz, CDCl_3




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃ [contains some impurities (*)]




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




^{19}F NMR, 376 MHz, CDCl_3




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃



^{19}F NMR, 376 MHz, CDCl_3



Chemical structure of **(-)-15l** is shown. The ^1H NMR spectrum (CDCl₃) displays the following peaks and integrations:

- 7.2 ppm (triplet, 13.66H)
- 7.1 ppm (multiplet, 2.02H)
- 3.9 ppm (multiplet, 2.13H)
- 3.5 ppm (multiplet, 2.02H)
- 3.2 ppm (multiplet, 1.06H)
- 3.0 ppm (multiplet, 1.01H)
- 2.9 ppm (multiplet, 0.98H)
- 2.6 ppm (multiplet, 1.00H)
- 1.5 ppm (peak, H₂O)
- 0.0 ppm (peak, TMS)


(-)-15l

Cc1ccccc1N(Cc2ccccc2)C[C@H](C#N)Cc3ccccc3


¹³C NMR spectrum (CDCl₃) of (-)-15l. The spectrum shows peaks in the aromatic region (118.51–137.57 ppm), a quaternary carbon (124.91 ppm), a nitrile carbon (122.01 ppm), and aliphatic carbons (32.79–36.59 ppm). Solvent peaks for CDCl₃ are visible at 77.16, 77.48, and 77.84 ppm.

Region	Chemical Shifts (ppm)
Aromatic	137.57, 136.29, 130.70, 129.22, 129.15, 129.11, 128.91, 128.03, 127.80, 127.72, 127.71, 127.61, 127.01, 118.51
Quaternary Carbon	124.91
Nitrile	122.01
Aliphatic	36.59, 32.79
Solvent (CDCl ₃)	77.16, 77.48, 77.84


¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃




¹³C NMR, 100 MHz, CDCl₃




¹⁹F NMR, 376 MHz, CDCl₃




¹H NMR, 400 MHz, CDCl₃



¹³C NMR, 100 MHz, CDCl₃



^{19}F NMR, 376 MHz, CDCl_3



Chemical structure of compound 18 is shown. The ^1H NMR spectrum (CDCl₃) displays peaks from 0.92 to 7.37 ppm. Key features include a multiplet at 7.2-7.4 ppm (aromatic, 7H), a multiplet at 4.9-5.0 ppm (OCH₂, 2H), a multiplet at 1.3-1.4 ppm (CH₂, 2H), and a multiplet at 0.9-1.0 ppm (CH₃, 3H). Integration values are provided for several regions: 7.01, 1.01, 1.91, 0.77, 0.96, 1.86, 1.08, 0.96, 0.96, 2.01, 1.09, 3.05, 2.96, and 3.00. Solvent peaks for H₂O and grease are also indicated.

Chemical structure of **(-)-18** is shown. The ^{13}C NMR spectrum (ppm) is displayed below the structure, with peaks labeled with their corresponding chemical shifts. The spectrum shows a range from 172.46 ppm to 18.02 ppm. An inset shows a zoomed-in view of the 51.2-52.3 ppm region.

Chemical structure of **(-)-18**: CC(C)C[C@H](Oc1ccccc1)C(=O)N[C@@H](C(F)(F)F)[C@H](C)NC(=O)OCc2ccccc2

^{13}C NMR peaks (ppm): 172.46, 157.63, 156.37, 135.98, 129.96, 128.72, 128.59, 128.45, 128.36, 125.86, 122.05, 120.23, 116.52, 123.05, 122.29, 120.23, 120.23, 77.48, 77.16, 76.84, 74.53, 67.43, 52.51, 52.22, 51.93, 51.64, 50.63, 39.17, 24.55, 23.37, 22.12, 18.02.

Inset peaks (ppm): 52.51, 52.22, 51.93, 51.64.

¹⁹F NMR, 376 MHz, CDCl₃

